<DOC>
	<DOCNO>NCT02596477</DOCNO>
	<brief_summary>The purpose study evaluate whether vepoloxamer provide blood chemical marker functional benefit damage heart muscle cell . This evaluated measurement blood-based laboratory marker , exercise tolerance , echocardiogram . In addition , safety blood level vepoloxamer subject chronic heart failure evaluate .</brief_summary>
	<brief_title>Evaluation Vepoloxamer Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age 18 74 Duration document heart failure &gt; 3 month On stable concomitant medication regimen ≥4 week Left ventricular ejection fraction ≤35 % Systolic blood pressure ≥90 mmHg Severe valvular stenosis primary valvular regurgitation cause heart failure History myocardial infarction , coronary artery bypass graft surgery , percutaneous intervention within prior 3 month Estimated glomerular filtration rate ≤45 mL/min/1.73 m2 Acutely decompensated heart failure within 1 month prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Heart failure</keyword>
</DOC>